2023-2027 Global Hemostasis Analyzers and Reagents USA, Europe, Japan Chromogenic, Immunodiagnostic, Molecular Coagulation Test Volume and Sales Segment Forecasts for Hospitals, Commercial/Private Labs and POC Locations 2023 Competitive Shares and Growth Strategies, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

October 2023 | | ID: 221A027D79C5EN
Venture Planning Group

Abstracts

SummaryThis comprehensive seven-country report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the global coagulation testing market during the next five years.The report is available by section, and can be customized to specific information needs and budget.The report explores business and technological trends in the US, Europe (France, Germany, Italy, Spain, UK) and Japan; provides estimates of the test volume, as well as sales and market shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.RationaleThe growing cost-containment pressures in major industrialized nations, coupled with continued technological advances in chromagenic substrates, monoclonal antibodies, immunoassays, molecular diagnostics, computers and laboratory automation will radically change the global coagulation diagnostics practice during the next five years.

New specific and sensitive markers of coagulation will be increasingly used on automated instrumentation. Coagulation testing will also become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the coagulation testing closer to the patient, thus creating additional opportunities and challenges for suppliers.

Coagulation Tests Analyzed in the Report

Activated Clotting Time (ACT) (1), Activated Protein C Resistance, Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time, D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII, Factor IX, Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII, Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre-Kallikrein Factor Activation, Heparin/Anti-Factor Xa, Heparin-Induced Thrombocytopenia, Plasmin, Plasminogen, Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S, Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Thrombin Time, Von Willebrand's Factor Fav/Ag, and others.

Geographic Coverage

France, Germany, Italy, Japan, Spain, UK, USA

Competitive Assessments

Extensive strategic profiles of major suppliers and emerging market entrants.

Current and Emerging Products

Review of established and emerging procedures.

Comparison of automated and semi-automated analyzers marketed by Diagnostica Stago, Helena, IL, Siemens, Sysmex and other suppliers.

Technology Review

Analysis of current and emerging technologies and their potential market applications.

Companies developing or marketing new technologies and products by test.

Strategic Recommendations

Product development and business expansion opportunities with significant market appeal.

Ideal product models with tentative prices and operating characteristics.

Alternative market penetration strategies for instrument and reagent suppliers.

• Potential market entry barriers and risks.

Contents

I. INTRODUCTION

II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

IV. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets

V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VI. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Major Routine and Special Coagulation Tests
1. Introduction
2. Activated Partial Thromboplastin Time (APTT)
3. Alpha-2 Antiplasmin
4. Antithrombin III
5. Bleeding Time
6. D-Dimer
7. Ethanol Flocculation Test
8. Euglobulin Lysis
9. Factor Assays
a. Introduction
b. Factor II
c. Factor V/Factor V Leiden
d. Factor VII
e. Factor VIII
f. Factor IX
g. Factor IXa
h. Factor X (Stuart Factor)
i. Factor Xa
j. Factor XI
k. Factor XII
l. Factor XIII
Table of Contents (continued)
10. Fibrin Degradation Products
11. Fibrinogen
12. Heparin
13. Hirudin
14. Hypercoagulability and Thrombosis
15. Lipoprotein a
16. Plasmin
17. Plasminogen
18. Plasminogen Activator Inhibitor (PAI)
19. Platelet Function Tests
20. Platelet Aggregation
21. Proteins C and S
22. Prothrombin Fragment 1.2
23. Prothrombin Time (PT)
24. Reptilase Time
25. Thrombin Time
26. Tissue-Type Plasminogen Activator (t-PA)
27. Von Willebrand's Factor
B. Coagulation Instrumentation Review: Centralized
and POC Testing Analyzers
C. Major Coagulation Testing Technologies
and Their Potential Applications
1. Chromogenic Substrates
2. Monoclonal and Polyclonal Antibodies
3. Immunoassays
4. Molecular Diagnostics
5. Microcomputers
6. Automation
7. Robotics
8. Artificial Intelligence
9. Dry Chemistry
10. Bisensors

VII. COUNTRY MARKET SIZE, TEST VOLUME

and Sales Forecasts by Segment, Major
Instrument and Reagent Suppliers Market
Shares
Table of Contents (continued)

VIII. COMPETITIVE ASSESSMENTS

The report provides strategic assessments of over 20 leading coagulation market
players and start-up companies with innovative technologies and products,
including:
Abbott
Beckman Coulter/Danaher
Becton Dickinson
Diagnostica Stago
Grifols
Helena Laboratores
IL/Werfen
Roche
Sekisui Diagnostics
Siemens Healthineers
Sysmex
Thermo Fisher, and others